Parveen, Sadiya
Shen, Jessica
Lun, Shichun
Zhao, Liang http://orcid.org/0000-0002-2126-6778
Alt, Jesse
Koleske, Benjamin
Leone, Robert D.
Rais, Rana
Powell, Jonathan D.
Murphy, John R.
Slusher, Barbara S.
Bishai, William R. http://orcid.org/0000-0002-8734-4118
Article History
Received: 3 March 2023
Accepted: 6 November 2023
First Online: 16 November 2023
Competing interests
: S.P., J.S., S.L., L.Z., B.K., J.R.M. and W.R.B. declare no conflict of interest. J.A., R.R., J.D.P. and B.S.S. are inventors on multiple Johns Hopkins University (JHU) patents covering glutamine antagonist prodrugs including JHU083 and their utility. These patents have been licensed to Dracen Pharmaceuticals Inc. R.R., J.D.P. and B.S.S. are founders of and hold equity in Dracen Pharmaceuticals Inc. This arrangement has been reviewed and approved by the JHU in accordance with its conflict-of-interest policies. R.D.L. is an inventor on US patent 10842763 submitted by Johns Hopkins University and licensed to Dracen Pharmaceuticals that covers the use of glutamine analogues, such as JHU083 (DRP-083), for cancer immunotherapy. The authors declare no other competing interests.